Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286892 · ClinicalTrials.gov registry record · NA
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Louise Reagan.
- Recruiting
- Registry status
- NA
- Development phase
- 128
- Enrollment target
- 2
- Study locations
NCT05286892: Recruiting NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Louise Reagan.
NCT05286892 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Louise Reagan. The registered enrollment target is 128 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05286892, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Louise Reagan.
- RECRUITING
- Registry status
- NA
- Development phase
- 128 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study will use a randomized clinical trial design with non-equivalent control group and longitudinal design to evaluate the feasibility, acceptability, and preliminary effects of the Diabetes LIVE JustICE application. The design will incorporate repeated measures at 0, 6, and 12 weeks. Outcome variables will include recruitment assessments, participation, engagement, user experience, and measures proximally related to behavior change - e.g., diabetes knowledge, diabetes-related distress, diabetes self-care, and social support and clinical outcomes -e.g., glycemic control. Focus group interviewing will be conducted to evaluate acceptability among intervention group participants.
Primary Outcome
Demographic data (race/ethnicity, marital status, income (categorical), educational attainment, employment, age, sex, and disease duration).
Conditions Studied
Interventions
- OTHER Diabetes LIVE JustICE
- OTHER Enhanced Education
Study Locations (2)
Connecticut
- University of Connecticut - Storrs
- University of Connecticut - Storrs Mansfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2023-04-30 |
| Est. Completion | 2026-12-15 |
| Phase | NA |
What NCT05286892 shows while recruiting
NCT05286892 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Diabetes LIVE JustICE is the first listed.
NCT05286892 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05286892 about?
NCT05286892 is a clinical study titled "Diabetes Learning in Virtual Environments Just in Time for Community Reentry". The proposed study will use a randomized clinical trial design with non-equivalent control group and longitudinal design to evaluate the feasibility, acceptability, and preliminary effects of the Diabetes LIVE JustICE application. The design will incorporate repeated measures at 0, 6, and 12 weeks. ...
What is the current status of trial NCT05286892?
This trial is currently recruiting. It is a NA study. The enrollment target is 128 participants. The study started on 2023-04-30. Estimated completion is 2026-12-15.
What conditions does trial NCT05286892 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT05286892?
The interventions under investigation include: Diabetes LIVE JustICE (OTHER), Enhanced Education (OTHER).
Who is sponsoring clinical trial NCT05286892?
This trial is sponsored by Louise Reagan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05286892 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05286892's enrollment target sits among peer trials
128 186th of 348 higher than 163 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Efficacy of Using Mobile Health Applications for Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI